Fig. 5.
Fig. 5. Actuarial risk of relapse after allogeneic BMT for patients with refractory anemia ± ringed sideroblasts (RA/RARS; n = 14) and all other diagnoses (n = 46).

Actuarial risk of relapse after allogeneic BMT for patients with refractory anemia ± ringed sideroblasts (RA/RARS; n = 14) and all other diagnoses (n = 46).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal